Author(s):
Akhil P R, Jino Vincent, Siby Gopinath
Email(s):
prakhil9397@gmail.com
DOI:
10.52711/0974-360X.2022.00936 
Address:
Akhil P R1*, Jino Vincent2, Siby Gopinath3
1Pharm D Intern, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India – 682041.
2Senior Resident, Department of Neurology, Amrita School of Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India – 682041.
3Professor, Department of Neurology, Amrita Advanced Centre for Epilepsy, Amrita Comprehensive Sleep Centre,
Amrita School of Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India – 682041.
*Corresponding Author
Published In:
Volume - 15,
Issue - 12,
Year - 2022
ABSTRACT:
Steroids have been used for a wide spectrum of indications in clinical practice. The potential benefits of steroids outweigh the complications in most settings. Steroids have been used over the counter in our country for allergy and arthritis. Here we present a case of a young girl who presented with headache, tinnitus, vomiting, and papilledema, visual field defect in perimetry with elevated IOP, presumed secondary to intranasal steroid use for allergic rhinitis. There are case reports suggesting a causal relationship between steroids and benign intracranial hypertension. Here patient on follow-up had significant improvement on stopping steroid spray. This case report is to highlight the need for awareness of the possibility of benign intracranial hypertension in patients who are on inhalational steroids.
Cite this article:
Akhil P R, Jino Vincent, Siby Gopinath. Benign Intracranial Hypertension Secondary to Intranasal Corticosteroid Administration. Research Journal of Pharmacy and Technology 2022; 15(12):5548-0. doi: 10.52711/0974-360X.2022.00936
Cite(Electronic):
Akhil P R, Jino Vincent, Siby Gopinath. Benign Intracranial Hypertension Secondary to Intranasal Corticosteroid Administration. Research Journal of Pharmacy and Technology 2022; 15(12):5548-0. doi: 10.52711/0974-360X.2022.00936 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-12-30
REFERENCES:
1. Roy AG et al. Idiopathic intracranial hypertension in pediatric population: Case series from India. Neurology India. 2013 Sep 1;61(5): 488. doi: 10.4103/0028-3886.121915
2. Williams DM. Clinical pharmacology of corticosteroids. Respiratory care. 2018 Jun 1;63(6):655-70. doi: https://doi.org/10.4187/respcare.06314
3. Deepalakshmi M, Kumar KV, Nandini R, Hriatmawii NH, Arun KP. Drug Utilization Evaluation of Corticosteroids at Secondary Care Public Hospital in Tamil Nadu. Research Journal of Pharmacy and Technology. 2019;12(11):5456-60. doi: http://dx.doi.org/10.5958/0974-360X.2019.00946.6
4. Imam S, Sharma P, Mehta DK, Joshi S, Das R. Corticosteroid utilization pattern: A prospective study at a tertiary care teaching Hospital. Research Journal of Pharmacy and Technology. 2020 Aug 12;13(8):3697-701. doi: 10.5958/0974-360X.2020.00654.X
5. Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner Journal. 2014 Jun 20;14(2):203-7.
6. Xu J et al. A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. Journal of pharmacokinetics and pharmacodynamics. 2007 Jun;34(3):355-72. doi: https://doi.org/10.1007/s10928-007-9050-8
7. Barnes PJ et al. Efficacy and safety of inhaled corticosteroids: new developments. American journal of respiratory and critical care medicine. 1998 Mar 1;157(3):S1-53. doi: https://doi.org/10.1164/ajrccm.157.3.157315
8. Dykewicz MS et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Annals of Allergy, Asthma & Immunology. 1998 Nov 1;81(5):478-518. doi: https://doi.org/10.1016/S1081-1206(10)63155-9
9. Robinson DS, Geddes DM. Inhaled corticosteroids: benefits and risks. Journal of Asthma. 1996 Jan 1;33(1):5-16. doi: https://doi.org/10.3109/02770909609077758
10. Derendorf H et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal. 2006 Nov 1;28(5):1042-50. doi: 10.1183/09031936.00074905
11. Kulkarni RR, Phadtare DG, Saudagar RB. UV spectrophotometric Method development and validation of Fluticasone propionate. Asian Journal of Research in Pharmaceutical Science. 2016 Jun 1;6(2). doi: https://doi.org/10.5958/2231-5659.2016.00019.9
12. Kurian AP, Dhanapal Y. Chronomodulated Drug Delivery System of Salmeterol Fluticasone Nlcs Loaded Tablets: Preparation, Characterization, Stability and Drug Release Studies for Management of Asthma. Asian Journal of Research in Pharmaceutical Sciences. 2021 May 10;11(2):95-102. doi: https://doi.org/10.52711/2231-5659.2021-11-2-1
13. Shah VV, Patil SJ, Shah ND. Multicomponent Estimation of Salmeterol xinafoate and Fluticasone Propionate in Bulk and Capsule Dosage Form by Ultraviolet Spectroscopy. Asian Journal of Research in Chemistry. 2011 Aug 28;4(8):1262-4.
14. Murali M, Kothandan S, Chandrasekaran M, Singh SK, Kuppusamy G, Radhakrishnan A. Fluticasone and Cyclophosphamide towards the track of personalized Medicine. Research Journal of Pharmacy and Technology. 2021 Jan 29;14(1):179-84. doi: https://doi.org/10.5958/0974-360X.2021.00031.7
15. Maurya PR, Joshi YM, Kadam VJ. A review of bronchial asthma. Res J Pharmacol Pharmacodynamics. 2013 Jul 1;5(4):257-65.
16. Raissy HH et al. Inhaled corticosteroids in lung diseases. American journal of respiratory and critical care medicine. 2013 Apr 15;187(8):798-803. doi: https://doi.org/10.1164/rccm.201210-1853PP
17. Liu D et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma & Clinical Immunology. 2013 Dec;9(1):1-25. doi: https://doi.org/10.1186/1710-1492-9-30
18. Waljee AK et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. bmj. 2017 Apr 12;357. doi: https://doi.org/10.1136/bmj.j1415
19. Thurtell MJ et al. An update on idiopathic intracranial hypertension. Reviews in neurological diseases. 2010;7:e56.
20. Newton M, Cooper BT. Benign intracranial hypertension during prednisolone treatment for inflammatory bowel disease. Gut. 1994 Mar 1;35(3):423-5. doi: http://dx.doi.org/10.1136/gut.35.3.423
21. Dhole AR, Shendage GG, Pethkar S, Magdum CS, Mohite SK. Drug used in inflammatory bowel disease (IBD)-Brief review. Research Journal of Pharmacology and Pharmacodynamics. 2014 Jul 1;6(3):153-61.
22. Gouda V, Shastry CS, Mateti UV, Subrahmanya C, Chand S. Study on steroid utilization patterns in general medicine department. Research Journal of Pharmacy and Technology. 2019 Oct 12;12(10):4771-6. doi: https://doi.org/10.5958/0974-360X.2019.00823.0
23. Dave PH. Pathogenesis and Novel Drug for Treatment of Asthma-A Review. Research Journal of Pharmacy and technology. 2016 Sep 1;9(9):1519. doi: https://doi.org/10.5958/0974-360X.2016.00297.3
24. Bond DW et al. Benign intracranial hypertension secondary to nasal fluticasone propionate. Bmj. 2001 Apr 14;322(7291):897. doi: https://doi.org/10.1136/bmj.322.7291.897